A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

Study identifier:D7260C00012

ClinicalTrials.gov identifier:NCT06996886

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-Label, Randomized, Four-Treatment, Four-Period, Single-Dose Crossover Study in Healthy Participants to Assess the Relative Bioavailability of AZD5004 in Three Solid Oral Formulations (F1, F3, F4)

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5004

Sex

All

Actual Enrollment

16

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 22 May 2025
Estimated Primary Completion Date: 20 Jul 2025
Estimated Study Completion Date: 21 Jul 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria